electroCore Provides Business Update and Select First Quarter 2020 Guidance - Seite 3

March 31, 2020 cash: The company ended the first quarter of 2020 with approximately $15.6 million of cash, cash equivalents and marketable securities. Subsequent to the end of the quarter, electroCore raised gross proceeds of approximately $3.1 million through a partial draw down from its recently announced $25 million stock purchase agreement with Lincoln Park Capital. 

The company intends to provide a more detailed operational and financial update during its first quarter conference call in mid-May.

About gammaCore
gammaCore (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. 

gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults. The National Institute for Health and Care Excellence (NICE) recommend gammaCore for use in the treatment of Cluster Headache. gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients.

• Safety and efficacy of gammaCore have not been evaluated in the following patients:
  -- Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device 
  -- Patients diagnosed with narrowing of the arteries (carotid atherosclerosis) 
  -- Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy) 
  -- Pediatric patients 
  -- Pregnant women 
  -- Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
• Patients should not use gammaCore if they: